- TEOXANE SA RHA® portfolio: first and only range of FDA -approved dermal fillers for correction of dynamic wrinkles - - Revance gains access to the growing $1.1B U.S. filler market with three differentiated products, and plans to launch in second quarter 2020 - - Fast-tracks Revance’s commercial

NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P.

NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update and shared anticipated

DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction NEWARK, Calif. --(BUSINESS WIRE)--Dec. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic

NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public

NEWARK, Calif. ,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public

- Appointment completes build-out of Revance’s commercial leadership team following submission of the Company’s Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for Injection (DAXI) - NEWARK, Calif. --(BUSINESS WIRE)--Dec.

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics License Application (BLA) to

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare